Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Featured trial
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients with Neutrophilic Skin Diseases

A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients with Neutrophilic Skin Diseases

  • 592 views
  • 25 Mar, 2021
  • 1 location
Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis

Crohn's disease. Vedolizumab, a novel biologic agent, is a recombinant humanized monoclonal antibody that specifically antagonizes intestine-selective α4β7 integrins on the surface of leukocyte subsets

inflammatory bowel disease
monoclonal antibodies
vedolizumab
antibiotics
crohn's disease
  • 0 views
  • 09 Aug, 2022
  • 1 location
Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia

The purpose of this study is to proof the safety and efficacy of a single bilateral subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia.

  • 12 views
  • 10 Apr, 2021
  • 1 location
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo (TILDVIT-1227)

Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with vitiligo.

hypopigmentation
  • 0 views
  • 28 Apr, 2022
  • 1 location
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis

Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction and myocardial dysfunction are impaired in patients with psoriasis compared to normal controls ,coronary artery disease patients and untreated hypertension subjects. The investigators also examined the effect of treatment …

Accepts healthy volunteers
etanercept
cyclosporine
apremilast
atherosclerosis
  • 0 views
  • 18 Apr, 2022
  • 1 location
Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders (SUNSTAR)

Rheumatoid arthritis (RA) is the most common inflammatory rheumatoid disease in France, affecting 0.3% of the general population. Without effective treatment, the persistent inflammation causes invalidating pain and joint destruction, leading to major functional disability. Biological agents have been proposed for patients with RA who have the most severe form …

tumor necrosis factor
abatacept
DMARD
tocilizumab
roactemra
  • 11 views
  • 13 Feb, 2022
  • 1 location
Study on the Safety for the Newborn of the Use of Biologics During Pregnancy by Mothers Affected by Autoimmune Diseases (BIOGN1)

The goal of the study is to evaluate the effects on the offspring and therefore the safety of using biologic agents during pregnancy and their eventual consequences on children. The effects considered are divided into peri-partum and more long-term effects. Demonstration of safety in children born from mothers who received …

  • 0 views
  • 20 Feb, 2022
  • 1 location
Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents

to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter

metastasis
primary malignant neoplasm
cancer
Accepts healthy volunteers
metastases
  • 7 views
  • 19 Sep, 2022
  • 1 location
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study (EVOLVE)

The main aim of this study is to compare long-term remission in participants receiving vedolizumab (VDZ) and those receiving ustekinumab (UST). In this study, the study doctors will review each participant's past medical records. This study is about collecting existing information only; participants will not receive treatment or need to …

remission
crohn's disease
vedolizumab
ustekinumab
  • 0 views
  • 18 Sep, 2022
  • 29 locations
Circulating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study (CITCCA)

study is planned where patients with positive ctDNA 4-6 weeks after radical surgery will be randomised to chemotherapy and/or a biologic agent.

  • 0 views
  • 02 May, 2022
  • 5 locations